SIAIS178

Overview

SIAIS178 is a potent and selective BCR-ABL degrader based on PROTAC technology with an IC 50 of 24 nM. SIAIS178 causes effective degradation of BCR-ABL protein by recruiting Von Hippel-Lindau (VHL) E3 ubiquitin ligase . SIAIS178 has anticancer activity. (Pink: Bcr-Abl ligand ( HY-107447 ); Blue: VHL ligand ( HY-125845 ); Black: linker ( HY-W015300 )).

Application

Products | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Parkinson's Disease | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Signaling Pathways > PROTAC | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > PROTACs | Products > Signaling Pathways > Bcr-Abl

Product Information

• Catalog No.: HY-128756
• CAS No.: 2376047-73-1
• Molecular Formula: C50H62ClN11O6S2
• Molecular Weight: 1012.68
• Purity: 98.64%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: ≥ 7.5 mg/mL (7.41 mM); Clear solution
• Availability: In-stock

Source

Original product source